



**Lee's Pharmaceutical Holdings
Limited**
李氏大藥廠控股有限公司

**Lee's Pharmaceutical Enters into Agreement with CID S.r.l.
obtaining Exclusive Distribution of PTCA Balloon Catheters, Chrono
Carbostent and Optima DES Carbostent in China**

[30 December 2010 - Hong Kong] **Lee's Pharmaceutical Holdings Limited** ("**Lee's Pharmaceutical**" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced that the Group has entered into an exclusive agreement with Carbostent & Implantable Devices S.r.l. ("CID") for the distribution of BRIO PTCA Balloon Catheters, FLUYDO PTCA Balloon Catheters, CHRONO Carbostent and OPTIMA DES Carbostent aimed at treating coronary artery disease in China.

CID is an independent Italian company with a wealth of background and expertise gained in over a decade of research, development and proven clinical experience in the treatment of vascular disease.

Percutaneous transluminal coronary angioplasty (" PTCA ") has been adopted as a major treatment strategy for patients with cardiovascular disease in China and the use of stent implementation has grown rapidly. Chinese stent market has entered a new phase of growth since 2009 due to significantly increasing insurance coverage and affordability. The Chinese stent market (end hospital sales) was US\$827m in 2009. Cardiovascular artery diseases (CAD) treatment is one of the fastest growing market segments in China, caused by rising prevalence, increasing affordability, improving infrastructure for treatment and over 1 billion population base. CAD is the second leading cause of cardiovascular death among the Chinese population. Prevalence rate of CAD is accelerating in China in recent years due to rising co-morbid conditions such as hypertension, hyperlipidemia, obesity, diabetes, as well as a rapidly aging population and a large number of smokers.

“We are excited to be CID’s partner in China for PTCA Balloon Catheters and Carbostent, which results in strengthening the cardiovascular product pipeline of the Group to 10 products and enhancing further penetration into the cardiovascular product market,” said Dr. Benjamin Li, CEO of the Group. “As a biochemical company focusing on cardiovascular disease in China, Lee’s Pharmaceutical is well positioned to tap into the rapidly growing market. We are forecasting a significant growth for PTCA procedure and we are confident that these products will contribute significantly to the revenue and profit of our Group in the future.”

Information about Lee’s Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited, a biopharmaceutical company, was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited in 2010, with over 15 years operation in China’s pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing and sales and marketing in China with global perspective and it currently markets nine products in China. The Group focuses on many different areas such as cardiovascular diseases, dermatology, oncology, gynecology and others with more than 22 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies.

Disclaimer

Information presented in this press release is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Company”). The Company makes no representation regarding, and assumes no responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information contained herein. In addition, the information contains projections and forward-looking statements that may reflect the Company’s current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s assumptions are correct. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company’s financial or trading position or prospects.